Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.626041
Title: Evaluation of prenatal adenoviral vascular endothelial growth factor gene therapy in the growth-restricted sheep fetus and neonate
Author: Carr, D.
Awarding Body: University College London (University of London)
Current Institution: University College London (University of London)
Date of Award: 2013
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Please try the link below.
Access from Institution:
Abstract:
Background - Fetal growth restriction (FGR) is associated with reduced uterine blood flow (UBF). In normal sheep pregnancies, adenovirus (Ad) mediated over-expression of vascular endothelial growth factor (VEGF) in the uterine arteries (UtA) increases UBF. It was hypothesised that enhancing UBF would improve fetal substrate delivery in an ovine paradigm of FGR characterised by reduced UBF from mid-gestation. Methods - Singleton pregnancies were established using embryo transfer in adolescent ewes subsequently overnourished to generate FGR (n=81). Ewes were randomised mid-gestation to receive bilateral UtA injections of 5x1011 particles Ad.VEGF-A165 or inactive treatment (saline or 5x1011 particles Ad.LacZ, a control vector). Fetal growth/wellbeing were evaluated using serial ultrasound. Late-gestation study: UBF was monitored using indwelling flowprobes until necropsy at 0.9 gestation. Vasorelaxation, neovascularisation in perivascular adventitia and placental mRNA expression of angiogenic factors/receptors were examined. A group of control-fed ewes with normally-developing fetuses was included (n=12). Postnatal study: Pregnancies continued until spontaneous delivery near to term. Lambs were weighed and measured weekly and underwent metabolic challenge at 7 weeks, dual-energy X-ray absorptiometry at 11 weeks, and necropsy at 12 weeks postnatal age. DNA methylation of somatotropic genes was examined in hepatic tissues. Results - Ultrasonographic fetal growth velocity was greater in Ad.VEGF-A165-treated versus control-treated FGR fetuses at 3-4 weeks post-injection. In late gestation fewer fetuses were markedly growth-restricted following Ad.VEGF-A165 therapy. There was evidence of mitigated brain sparing. No effect was seen on UBF/neovascularisation although Ad.VEGF-A165-transduced vessels showed enhanced vasorelaxation. Flt1/KDR expression was increased in the maternal placental compartment. At birth Ad.VEGF-A165-treated lambs tended to be heavier with increased placental efficiency. Postnatal growth, lean tissue accretion and insulin secretion were also increased, however no epigenetic changes were observed. Conclusions - Ad.VEGF-A165 safely increases fetal growth in this ovine model of FGR. This work has supported a successful application to translate this therapy into the clinic.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.626041  DOI: Not available
Share: